• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ultralife Corporation Completes Acquisition of Electrochem Solutions, Inc.

    11/1/24 7:00:00 AM ET
    $ITGR
    $ULBI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $ITGR alert in real time by email

    NEWARK, N.Y., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) completed its acquisition of all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR) on October 31, 2024.

    "I am thrilled to welcome Electrochem to the growing Ultralife Team as another valued member that shares our core values, operating philosophy and strong commitment to both our associates and our long-standing customers. Having achieved our target of closing the acquisition of Electrochem by the end of October, we now look forward to working closely with Khristine Carroll, President – Electrochem, and her experienced team to jointly implement our integration playbook. Together, we will advance our strategy of more fully realizing the operating leverage of our business model through scale and manufacturing cost efficiencies, while creating highly attractive opportunities to drive revenue growth through heightened cross-selling platforms and extending our reach into underserved adjacent markets that demand uncompromised safety, service, reliability and quality. I am confident that with Electrochem we will further increase our value to our customers and significantly strengthen our competitive position in our end markets, " said Mike Manna, President and Chief Executive Officer.

    Based in Raynham, MA and with over forty years of battery technology experience in critical applications, Electrochem designs and manufactures primary lithium metal and ultracapacitor cells and battery packs serving energy, military and various environmental, industrial and utility end markets on a global basis. For the trailing twelve-month period ended September 30, 2024, Electrochem recorded revenue of $34 million.

    Ultralife financed the transaction with a new Credit and Security Agreement with KeyBank, N.A. as administrative agent, along with M&T Bank and Community Bank as lenders.

    About Ultralife Corporation

    Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe. Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

    This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions or delays in our supply of raw materials and components due to business conditions, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

    Company Contact: Investor Relations Contact:
    Ultralife CorporationLHA
    Philip A. Fain Jody Burfening
    (315) 210-6110 (212) 838-3777
    [email protected][email protected]



    Primary Logo

    Get the next $ITGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITGR
    $ULBI

    CompanyDatePrice TargetRatingAnalyst
    Integer Holdings Corporation
    $ITGR
    5/22/2025$140.00Neutral → Buy
    Citigroup
    Integer Holdings Corporation
    $ITGR
    3/28/2025$145.00Outperform
    Raymond James
    Integer Holdings Corporation
    $ITGR
    2/21/2025Outperform → Perform
    Oppenheimer
    Integer Holdings Corporation
    $ITGR
    12/3/2024$160.00Overweight
    Wells Fargo
    Integer Holdings Corporation
    $ITGR
    7/16/2024$135.00Outperform
    Oppenheimer
    Integer Holdings Corporation
    $ITGR
    5/15/2024$137.00Buy
    Truist
    Integer Holdings Corporation
    $ITGR
    4/15/2024$105.00 → $135.00Neutral → Buy
    BofA Securities
    Integer Holdings Corporation
    $ITGR
    3/14/2024$137.00Buy
    CL King
    More analyst ratings

    $ITGR
    $ULBI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Whitmore Bradford T bought $64,778 worth of shares (11,980 units at $5.41) (SEC Form 4)

      4 - ULTRALIFE CORP (0000875657) (Issuer)

      5/28/25 4:16:03 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Director Whitmore Bradford T bought $148,475 worth of shares (27,160 units at $5.47) (SEC Form 4)

      4 - ULTRALIFE CORP (0000875657) (Issuer)

      5/15/25 4:25:37 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Director Saeli Thomas Louis bought $27,200 worth of Common Stock; $.10 par value (5,000 units at $5.44), increasing direct ownership by 6% to 85,000 units (SEC Form 4)

      4 - ULTRALIFE CORP (0000875657) (Issuer)

      5/14/25 4:54:27 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous

    $ITGR
    $ULBI
    Financials

    Live finance-specific insights

    See more
    • Ultralife Corporation Reports First Quarter Results

      NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Communications Systems salesGross profit of $12.7 million, or 25.1% of revenue, compared to $11.5 million, or 27.4% of revenue, for the 2024 first quarterOperating income of $3.4 million, including one-time non-recurring costs and purchase accounting adjustments of $0.4 million, compared to $4.1 million for the 2024 first quarterGAAP EPS of $0.11 comp

      5/9/25 7:00:00 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Ultralife Corporation to Report First Quarter Results on May 9, 2025

      NEWARK, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2025 before the market opens on Friday, May 9, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 10:00 AM ET on May 9, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BI00ee37974c5b4cbc86cd1d7ef099d998. This will e

      4/29/25 9:00:00 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Integer Announces CEO Succession Plan

      ~ Joseph Dziedzic to retire as President and CEO ~~ Payman Khales appointed President and CEO effective October 24, 2025 ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company's Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. "We

      4/24/25 8:01:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    $ULBI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Integer Holdings upgraded by Citigroup with a new price target

      Citigroup upgraded Integer Holdings from Neutral to Buy and set a new price target of $140.00

      5/22/25 8:16:14 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Raymond James initiated coverage on Integer Holdings with a new price target

      Raymond James initiated coverage of Integer Holdings with a rating of Outperform and set a new price target of $145.00

      3/28/25 8:19:38 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings downgraded by Oppenheimer

      Oppenheimer downgraded Integer Holdings from Outperform to Perform

      2/21/25 6:56:47 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    $ULBI
    Leadership Updates

    Live Leadership Updates

    See more
    • Ultralife Corporation Expands Leadership Team to Drive Rapid Growth Plans

      NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife's products and solutions meet the evolving needs of our customers. Jeff brings over two

      1/6/25 7:00:00 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Ultralife Corporation Names Michael E. Manna President & CEO

      NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation ("Ultralife" or the "Company") (NASDAQ:ULBI) has appointed Michael E. Manna as the Company's President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec will remain with Ultralife as an employee for a sixty-day period ending January 20, 2023 in an advisory role to ensure a smooth leadership transition. In addition to his new role, Mike Manna will retain his leadership position for the Company's Battery & Energy Products segment which he held prior to his appointment as President & CEO. "Over the past twe

      11/22/22 4:30:00 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous

    $ITGR
    $ULBI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ultralife Corporation Reports First Quarter Results

      NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Communications Systems salesGross profit of $12.7 million, or 25.1% of revenue, compared to $11.5 million, or 27.4% of revenue, for the 2024 first quarterOperating income of $3.4 million, including one-time non-recurring costs and purchase accounting adjustments of $0.4 million, compared to $4.1 million for the 2024 first quarterGAAP EPS of $0.11 comp

      5/9/25 7:00:00 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Ultralife Corporation to Report First Quarter Results on May 9, 2025

      NEWARK, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2025 before the market opens on Friday, May 9, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 10:00 AM ET on May 9, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BI00ee37974c5b4cbc86cd1d7ef099d998. This will e

      4/29/25 9:00:00 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Integer to Present at Bank of America Securities Health Care Conference on May 14

      PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health Care Conference, to be held May 13-15, 2025, in Las Vegas. Members of the Integer executive leadership team will participate in a fireside chat on Wednesday, May 14, at 10:00 a.m. PT. A live webcast of the presentation will be accessible under "News & Events" on the Investor Relations section of the Integer website at investor.integer.net. Learn more about Integer at www.integer.net. About Integer®Integer Holdings Corporation (NYSE:I

      4/29/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    $ULBI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Ultralife Corporation

      SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)

      9/3/24 4:15:14 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • SEC Form SC 13G filed by Ultralife Corporation

      SC 13G - ULTRALIFE CORP (0000875657) (Subject)

      2/14/24 1:50:40 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • SEC Form SC 13G/A filed by Ultralife Corporation (Amendment)

      SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)

      2/9/24 9:59:17 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous

    $ITGR
    $ULBI
    SEC Filings

    See more
    • SEC Form SD filed by Ultralife Corporation

      SD - ULTRALIFE CORP (0000875657) (Filer)

      5/28/25 8:56:13 AM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Integer Holdings Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      5/28/25 7:08:15 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by Ultralife Corporation

      DEFA14A - ULTRALIFE CORP (0000875657) (Filer)

      5/27/25 1:04:07 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous

    $ITGR
    $ULBI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Whitmore Bradford T bought $64,778 worth of shares (11,980 units at $5.41) (SEC Form 4)

      4 - ULTRALIFE CORP (0000875657) (Issuer)

      5/28/25 4:16:03 PM ET
      $ULBI
      Industrial Machinery/Components
      Miscellaneous
    • Director Passerini Filippo was granted 1,514 shares, increasing direct ownership by 5% to 29,147 units (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      5/23/25 4:48:03 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Antrum Sheila was granted 1,514 shares, increasing direct ownership by 18% to 10,102 units (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      5/23/25 4:47:41 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care